(S)-Methylisothiourea sulfate

Catalog No.S3631 Batch:S363101

Print

Technical Data

Formula

C2H6N2S.1/2 H2SO4

Molecular Weight 139.19 CAS No. 867-44-7
Solubility (25°C)* In vitro Water 27 mg/mL (193.97 mM)
DMSO Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description (S)-Methylisothiourea sulfate is a potent inhibitor of inducible NO synthase (iNOS).
Targets
iNOS [1]
In vitro S-Methylisothiourea sulfate (SMT) is at least 10- to 30-fold more potent as an inhibitor of inducible NOS (iNOS) in immunostimulated cultured macrophages (EC50, 6 microM) and vascular smooth muscle cells (EC50, 2 microM) than NG-methyl-L-arginine (MeArg) or any other NOS inhibitor yet known. The effect of SMT on iNOS activity can be reversed by excess L-arginine in a concentration-dependent manner. SMT is a competitive inhibitor of iNOS activity at the L-arginine site. SMT (up to 1 mM) does not inhibit the activity of xanthine oxidase, diaphorase, lactate dehydrogenase, monoamine oxidase, catalase, cytochrome P450, or superoxide dismutase. SMT is equipotent with MeArg in inhibiting the endothelial, constitutive isoform of NOS in vitro[2].
In vivo Treatment of the mice with S-methylisothiourea sulfate (SMT), a potent inhibitor of inducible NO synthase (NOS), prevents the elevation of serum NO levels and concomitantly reduces the enhanced response to pentylenetetrazole[1]. Therapeutic administration of SMT (5 mg/kg, i.p., given 2 hr after LPS, 10 mg/kg, i.p.) attenuates the rises in plasma alanine and aspartate aminotransferases, bilirubin, and creatinine and also prevents hypocalcaemia when measured 6 hr after administration of LPS. SMT (1 mg/kg, i.p.) improves 24-hr survival of mice treated with a high dose of LPS (60 mg/kg, i.p.)[2]. SMT is beneficial to myocardial contractility in this model of endotoxemia[3].

Protocol (from reference)

Cell Assay:[2]
  • Cell lines

    J774.2 macrophages

  • Concentrations

    10 nM-0.1 M

  • Incubation Time

    24 h

  • Method

    --

Animal Study:[1]
  • Animal Models

    ICR mice

  • Dosages

    2 mg/kg

  • Administration

    i.p.

Selleck's (S)-Methylisothiourea sulfate has been cited by 2 publications

Ultrasmall PtAu2 nanoclusters activate endogenous anti-inflammatory and anti-oxidative systems to prevent inflammatory osteolysis [ Theranostics, 2023, 13(3):1010-1027] PubMed: 36793859
Early secreted antigenic target of 6-kDa of Mycobacterium tuberculosis induces transition of macrophages into epithelioid macrophages by downregulating iNOS / NO-mediated H3K27 trimethylation in macrophages. [ Mol Immunol, 2020, 117:189-200] PubMed: 31816492

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.